HealthRock and Dr. Seibel Awarded Gates Foundation Award

HealthRock LLC announced today that it is a Grand Challenges Explorations winner, an initiative funded by the Bill & Melinda Gates Foundation.  Mache Seibel, MD will pursue an innovative global health and development research project, titled ­”Air-Infused Female Condom.” Grand Challenges Explorations (GCE) funds individuals worldwide to explore ideas that can break the mold in how we solve persistent global health and development challenges.

Dr Seibel’s project is one of over 50 Grand Challenges Explorations Round 12 grants announced today by the Bill & Melinda Gates Foundation. To receive funding, Mache Seibel, MD and other Grand Challenges Explorations Round 12 winners demonstrated in a two-page online application a bold idea in one of five critical global heath and development topic areas that included agriculture development, behavior change and looking into animal and human health.  Applications for the next Round will be accepted starting September 2014.




Dr. Mache Seibel, MD, OB/Gyn, one of the world’s leading experts on Women’s Health and Menopause, and the President of HealthRock LLC will lead a professional research team toward the optimization and FDA testing of a new Female Condom, called Femex. The key advantages of this US Patented (Leon B. Kassman/Condax Medical Products LLC) Class II medical device, beyond protection from pregnancy and sexually transmitted infections are: 1) Femex actively stimulates both partners pleasure-centers during intercourse; 2) Femex may be ‘in place’ for up to 8 hours prior to sexual activity; 3) Femex is designed to be withdrawn with the male.

The ‘silent’ polyurethane Femex condom is positioned using a novel insertion-wand, thereby limiting user contact and assuring easy, accurate, and quick placement. A totally new, self-contained, air-infusion system improves the ‘hold-in-place’ while creating additional gentle friction for both partners. Femex is projected to parallel existing condom cost in the same category.